(New Brunswick, NJ) -- Staff at the Food and Drug Administration are endorsing Johnson & Johnson's COVID-19 vaccine for emergency use. Staff explained the results from the clinical trial and its safety data were consistent with the FDA's coronavirus guidance recommendations. Johnson & Johnson explained the vaccine's level of protection was 72-percent effective in the U.S. while also preventing 100-percent of hospitalizations and death. The company added there were no reports of any allergic reaction. An advisory committee at the FDA will meet Friday to review Johnson & Johnson's request for emergency use authorization.